We undertook an in-depth investigation of the data pertaining to pancreatic adenocarcinoma (PAAD) to identify potential targets for the development of precision therapies.

Material and methods:
The construction of a protein-protein interaction (PPI) network was based on overlapping differentially expressed genes (DEGs) identified in the GSE16515, GSE32676, and GSE125158 datasets. A subsequent bioinformatic analysis was performed on the interconnected genes within the PPI network, leading to the identification of the central gene, CENPN. In vitro experimentation such as CCK8 and Transwell experiments was employed to elucidate the impact of CENPN expression patterns on PAAD cell proliferation, migration, and invasion. Furthermore, the investigation revealed through comprehensive enrichment analysis that the pivotal signaling pathway associated with CENPN is the p53 signaling pathway.

Following a comprehensive bioinformatic analysis of 161 concordant differentially expressed genes (DEGs) across three microarray datasets, CENPN emerged as the central gene under investigation. Overexpression of CENPN in pancreatic adenocarcinoma (PAAD) was associated with unfavorable patient outcomes and heightened sensitivity to four PAAD therapies: gemcitabine, docetaxel, paclitaxel, and sunitinib. Reduced CENPN expression impeded PAAD cell proliferation, migration, and invasion; however, these effects were counteracted upon upregulation of CENPN expression. Additionally, CENPN interacted with MDM2, promoting PAAD progression by targeting the p53 signaling pathway.

The findings of our study substantiate that CENPN is associated with the pathogenesis of PAAD. Consequently, CENPN appears to be a promising candidate for targeted precision therapy in clinical applications.

Yang C, Liu Z, Zeng X, et al. Evaluation of the diagnostic ability of laminin gene family for pancreatic ductal adenocarcinoma. Aging (Albany NY) 2019; 11: 3679-703.
Lin W, Noel P, Borazanci EH, et al. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions. Genome Med 2020; 12: 80.
Tang CC, Draucker C, Tejani M, Von Ah D. Symptom experiences in patients with advanced pancreatic cancer as reported during healthcare encounters. Eur J Cancer Care (Engl) 2018; 27: e12838.
Rettobyaan F, Widodo B. Palliative management of a patient with gastric outlet obstruction (GOO) due to caput pancreatic cancer during COVID-19 pandemic. Bali Med J 2023; 12: 744-8.
Olakowski M, Bułdak Ł. Modifiable and non-modifiable risk factors for the development of non-hereditary pancreatic cancer. Medicina (Kaunas) 2022; 58: 978.
Zanini S, Renzi S, Limongi AR, Bellavite P, Giovinazzo F, Bermano G. A review of lifestyle and environment risk factors for pancreatic cancer. Eur J Cancer 2021; 145: 53-70.
Koeppel F, Bobard A, Lefebvre C, et al. Added value of whole-exome and transcriptome sequencing for clinical molecular screenings of advanced cancer patients with solid tumors. Cancer J 2018; 24: 153-62.
Cree IA, Indave Ruiz BI, Zavadil J, et al. The international collaboration for cancer classification and research. Int J Cancer 2021; 148: 560-71.
Qian Y, Gong Y, Fan Z, et al. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol Oncol 2020; 13: 130.
Wang H, Lu L, Liang X, Chen Y. Identification of prognostic genes in the pancreatic adenocarcinoma immune microenvironment by integrated bioinformatics analysis. Cancer Immunol Immunother 2022; 71: 1757-69.
Ferguson LP, Gatchalian J, McDermott ML, et al. Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma. Nat Commun 2023; 14: 292.
Shi X, Zhao Y, He R, et al. Three-lncRNA signature is a potential prognostic biomarker for pancreatic adenocarcinoma. Oncotarget 2018; 9: 24248.
Zhou K, Gebala M, Woods D, et al. CENP-N promotes the compaction of centromeric chromatin. Nat Struct Mol Biol 2022; 29: 403-13.
Oka N, Kasamatsu A, Endo-Sakamoto Y, et al. Centromere protein N participates in cellular proliferation of human oral cancer by cell-cycle enhancement. J Cancer 2019; 10: 3728-34.
Wang Q, Yu X, Zheng Z, Chen F, Yang N, Zhou Y. Centromere protein N may be a novel malignant prognostic biomarker for hepatocellular carcinoma. Peer J 2021; 9: e11342.
Wu H, Zhou Y, Wu H, et al. CENPN Acts as a novel biomarker that correlates with the malignant phenotypes of glioma cells. Front Genet 2021; 12: 732376.
Zhao Y, Yu H, Hu W. The regulation of MDM2 oncogene and its impact on human cancers. Acta Biochim Biophys Sin 2014; 46: 180-9.
Giono LE, Manfredi JJ. Mdm2 is required for inhibition of Cdk2 activity by p21, thereby contributing to p53-dependent cell cycle arrest. Mol Cell Biol 2007; 27: 4166-78.
Toledo F, Wahl GM. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol 2007; 39: 1476-82.
Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet (London, England) 2020; 395: 2008-20.
Grossberg AJ, Chu LC, Deig CR, et al. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin 2020; 70: 375-403.
Singh RR, O’Reilly EM. New treatment strategies for metastatic pancreatic ductal adenocarcinoma. Drugs 2020; 80: 647-69.
Conroy T, Desseigne F, Ychou M, et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-25.
Kuang W, Wang X, Ding J, et al. PTPN2, a key predictor of prognosis for pancreatic adenocarcinoma, significantly regulates cell cycles, apoptosis, and metastasis. Front Immun 2022; 13: 805311.
Huang X, Zhang G, Tang T, Liang T. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development. Mol Cancer 2021; 20: 44.
Muniraj T, Jamidar PA, Aslanian HR. Pancreatic cancer: a comprehensive review and update. Dis Mon 2013; 59: 368-402.
Lin QJ, Yang F, Jin C, Fu DL. Current status and progress of pancreatic cancer in China. World J Gastroenterol 2015; 21: 7988.
De Dosso S, Siebenhüner AR, Winder T, et al. Treatment landscape of metastatic pancreatic cancer. Cancer Treat Rev 2021; 96: 102180.
Wang J, Lei K, Han F. Tumor microenvironment: recent advances in various cancer treatments. Eur Rev Med Pharmacol Sci 2018; 22: 3855-64.
Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-703.
Hamada K, Ueda M, Satoh M, Inagaki N, Shimada H, Yamada-Okabe H. Increased expression of the genes for mitotic spindle assembly and chromosome segregation in both lung and pancreatic carcinomas. Cancer Genomics Proteomics 2004; 1: 231-40.
Cao X, Yao N, Zhao Z, et al. LEM domain containing 1 promotes pancreatic cancer growth and metastasis by p53 and mTORC1 signaling pathway. Bioengineered 2022; 13: 7771-84.
Zhang Y, Chandra V, Riquelme Sanchez E, et al. Interleukin-17–induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. J Exp Med 2020; 217: e20190354.
Peng M, Zhang Q, Cheng Y, et al. Apolipoprotein AI mimetic peptide 4F suppresses tumor-associated macrophages and pancreatic cancer progression. Oncotarget 2017; 8: 99693.
Bie Q, Zhang B, Sun C, et al. IL-17B activated mesenchymal stem cells enhance proliferation and migration of gastric cancer cells. Oncotarget 2017; 8: 18914.
Lai XL, Huang YH, Li YS, et al. Differential expression profiling of microRNAs in para-carcinoma, carcinoma and relapse human pancreatic cancer. Clin Transl Oncol 2015; 17: 398-408.
Manoochehri H, Asadi S, Tanzadehpanah H, Sheykhhasan M, Ghorbani M. CDC25A is strongly associated with colorectal cancer stem cells and poor clinical outcome of patients. Gene Reports 2021; 25: 101415.
Wang X, Zhang K, Fu C, et al. High expression of centromere protein N as novel biomarkers for gastric adenocarcinoma. Cancer Rep (Hoboken) 2023; 6: e1798.
Wang Y, Li Y, Liu B, Song A. Identifying breast cancer subtypes associated modules and biomarkers by integrated bioinformatics analysis. Biosci Rep 2021; 41: BSR20203200.
Zheng Y, You H, Duan J, et al. Centromere protein N promotes lung adenocarcinoma progression by activating PI3K/AKT signaling pathway. Genes Genomics 2022; 44: 1039-49.
Gong Q, Dong Q, Zhong B, et al. Clinicopathological features, prognostic significance, and associated tumor cell functions of family with sequence similarity 111 member B in pancreatic adenocarcinoma. J Clin Lab Anal 2022; 36: e24784.
Xirodimas DP, Saville MK, Bourdon JC, Hay RT, Lane DP. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 2004; 118: 83-97.
Morita A, Yamamoto S, Wang B, et al. Sodium orthovanadate inhibits p53-mediated apoptosis. Cancer Res 2010; 70: 257-65.
Wu X, Wang L, Li Z. Identification of 3-phenylquinoline derivative PQ1 as an antagonist of p53 transcriptional activity. ACS Omega 2022; 7: 43180-9.
Journals System - logo
Scroll to top